Doxifluridine-d₃  (Synonyms: Ro 21-9738-d₃; 5-Fluoro-5'-deoxyuridine-d₃; 5'-DFUR-d₃)

Doxifluridine-d₃ is deuterated labeled Doxifluridine (HY-B0021). Doxifluridine has anticancer activity. Doxifluidine is a 5-FU prodrug. Doxifluridine is a thymidine synthase inhibitor. Doxifluridine can enhance tumor inhibition by synergizing with a variety of drugs^[1][2][3].

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[1].
Doxifluridine (1-10 μM) inhibits angiogenesis by significantly inhibiting the expression of VEGF in FU-MMT-1 cells^[2].
Doxifluridine (1-100 μM) slightly increases the expression of TSP-1 at low dose (1 μM) and inhibits the expression of TSP-1 at high dose (100 μM) in FU-MMT-1 cells^[2].
Doxifluridine (100 μM) inhibits cell proliferation in HUVEC cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Doxifluridine (61.55 mg/kg; Intragastric administration; Single dose) has anticancer activity in BALB ? cA Jcl-nu mice, and can significantly enhance anticancer activity in combination with TNP-470 (HY-101932)^[2].
Doxifluridine (200 mg/kg; Intraperitoneal injection; Single dose) can inhibit thymidine synthase activity in DMH-induced colon cancer mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

249.21

C₉H₈D₃FN₂O₅

3094-09-5

O[C@H]1[C@@H](O)[C@H](N2C(NC(C(F)=C2)=O)=O)O[C@@H]1C([2H])([2H])[2H]

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.  [Content Brief]

  [2]. Naganuma Y, et al. Metronomic doxifluridine chemotherapy combined with the anti-angiogenic agent TNP-470 inhibits the growth of human uterine carcinosarcoma xenografts. Cancer Sci. 2011 Aug;102(8):1545-52.  [Content Brief]

  [3]. Berne M, et al. Inhibition of thymidylate synthase after administration of doxifluridine in a transplantable colon carcinoma in the rat. Cancer Invest. 1988;6(4):377-83.  [Content Brief]

  [4]. Di Bartolomeo M, et al. Integrated treatment with doxifluridine and radiotherapy in recurrent or primary unresectable rectal cancer. A feasibility study. Tumori. 1999 May-Jun;85(3):211-3.  [Content Brief]